Predictors and surgical outcome of hemorrhagic metastatic brain malignancies - Takeaways - MDSpire

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies

  • By

  • Laurèl Rauschenbach

  • Pia Kolbe

  • Adrian Engel

  • Yahya Ahmadipour

  • Marvin Darkwah Oppong

  • Alejandro N. Santos

  • Sied Kebir

  • Celia Dobersalske

  • Björn Scheffler

  • Cornelius Deuschl

  • Philipp Dammann

  • Karsten H. Wrede

  • Ulrich Sure

  • Ramazan Jabbarli

  • May 27, 2024

  • 0 min

Share

  • 1

    Intracerebral metastases are the most common brain malignancy in adults, primarily from lung, breast, colorectal cancers, melanoma, and renal cell carcinoma.

  • 2

    Brain metastases are associated with a high risk of intracerebral hemorrhage, particularly from melanoma, kidney carcinoma, and hepatocellular carcinoma.

  • 3

    The study investigates hemorrhagic events in brain metastases from different tumor types and evaluates the safety of surgical tumor removal.

  • 4

    Inclusion criteria for the study required complete tumor resection and sufficient coagulation status prior to surgery, excluding certain conditions.

  • 5

    Clinical performance and prognosis were assessed using the Karnofsky Performance Status scale and the Recursive Partitioning Analysis classification.

Original Source(s)

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies

  • by Laurèl Rauschenbach, Pia Kolbe, Adrian Engel, Yahya Ahmadipour, Marvin Darkwah Oppong, Alejandro N. Santos, Sied Kebir, Celia Dobersalske, Björn Scheffler, Cornelius Deuschl, Philipp Dammann, Karsten H. Wrede, Ulrich Sure, Ramazan Jabbarli

  • May 27, 2024

Related Content

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Overcoming immunotherapy resistance in triple-negative breast cancer: a critical review of mast cell plasticity, metabolic reprogramming, and organoid models

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma